BR112022022800A2 - Métodos para tratamento de mieloma múltiplo - Google Patents
Métodos para tratamento de mieloma múltiploInfo
- Publication number
- BR112022022800A2 BR112022022800A2 BR112022022800A BR112022022800A BR112022022800A2 BR 112022022800 A2 BR112022022800 A2 BR 112022022800A2 BR 112022022800 A BR112022022800 A BR 112022022800A BR 112022022800 A BR112022022800 A BR 112022022800A BR 112022022800 A2 BR112022022800 A2 BR 112022022800A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- methods
- multiple myeloma
- relates
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Luminescent Compositions (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063023092P | 2020-05-11 | 2020-05-11 | |
US202063024209P | 2020-05-13 | 2020-05-13 | |
US202163159303P | 2021-03-10 | 2021-03-10 | |
PCT/EP2021/062364 WO2021228783A1 (en) | 2020-05-11 | 2021-05-10 | Methods for treating multiple myeloma |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022022800A2 true BR112022022800A2 (pt) | 2022-12-13 |
Family
ID=75870653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022022800A BR112022022800A2 (pt) | 2020-05-11 | 2021-05-10 | Métodos para tratamento de mieloma múltiplo |
Country Status (12)
Country | Link |
---|---|
US (1) | US11952426B2 (ko) |
EP (1) | EP4149628A1 (ko) |
JP (1) | JP2023524875A (ko) |
KR (1) | KR20230009450A (ko) |
CN (1) | CN116249548A (ko) |
AU (1) | AU2021272291A1 (ko) |
BR (1) | BR112022022800A2 (ko) |
CA (1) | CA3182697A1 (ko) |
IL (1) | IL298046A (ko) |
MX (1) | MX2022014166A (ko) |
TW (1) | TW202208429A (ko) |
WO (1) | WO2021228783A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020252366A1 (en) | 2019-06-14 | 2020-12-17 | Teneobio, Inc. | Multispecific heavy chain antibodies binding to cd22 and cd3 |
WO2024044548A1 (en) * | 2022-08-23 | 2024-02-29 | Janssen Biotech, Inc. | Teclistamab for the treatment of multiple myeloma |
US20240076376A1 (en) * | 2022-08-23 | 2024-03-07 | Janssen Biotech, Inc. | Approved products for the treatment of multiple myeloma |
WO2024095173A1 (en) * | 2022-11-02 | 2024-05-10 | Janssen Biotech, Inc. | Methods of treating cancers |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
AU690528B2 (en) | 1992-12-04 | 1998-04-30 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
ES2190087T3 (es) | 1997-06-13 | 2003-07-16 | Genentech Inc | Formulacion estabilizada de un anticuerpo. |
ATE462004T1 (de) | 1997-09-16 | 2010-04-15 | Centocor Inc | Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen |
US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
JP2004533997A (ja) | 2001-02-20 | 2004-11-11 | ザイモジェネティクス,インコーポレイティド | Bcma及びtaciの両者を結合する抗体 |
US20050276803A1 (en) | 2004-04-16 | 2005-12-15 | Genentech, Inc. | Method for augmenting B cell depletion |
AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
ES2592271T3 (es) | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos |
DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
BRPI0619056A2 (pt) | 2005-11-28 | 2011-09-20 | Genmab As | anticorpo monovalente, método para preparar e produzir um antcorpo monovalente, construção de ácido nucleico, célula hospedeira, imunoconjugado, uso de um anticorpo monovalente, e, composição farmacêutica |
WO2007117600A2 (en) | 2006-04-07 | 2007-10-18 | Macrogenics, Inc. | Combination therapy for treating autoimmune diseases |
US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
US20100183615A1 (en) | 2007-04-03 | 2010-07-22 | Micromet Ag | Cross-species-specific bispecific binders |
CN109456410B (zh) | 2007-04-03 | 2022-01-28 | 安进研发(慕尼黑)股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
ES2564523T3 (es) | 2007-12-19 | 2016-03-23 | Janssen Biotech, Inc. | Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos |
JP5739326B2 (ja) | 2008-04-25 | 2015-06-24 | ザイモジェネティクス, インコーポレイテッド | B細胞上でのbcmaタンパク発現レベル及び診断法における使用 |
PT2352763E (pt) | 2008-10-01 | 2016-06-02 | Amgen Res (Munich) Gmbh | Anticorpos biespecíficos de cadeia única com especificidade para antigénios-alvo com elevado peso molecular |
US10981998B2 (en) | 2008-10-01 | 2021-04-20 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
RS54900B1 (sr) | 2008-10-01 | 2016-10-31 | Amgen Res (Munich) Gmbh | Interspecijski specifično psmaxcd3 bispecifično jednolančano antitelo |
CA2741834C (en) | 2008-10-31 | 2022-04-05 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
AU2010213892B2 (en) | 2009-02-12 | 2014-10-23 | Janssen Biotech, Inc. | Fibronectin type III domain based scaffold compositions, methods and uses |
CN102421801B (zh) | 2009-03-10 | 2016-03-16 | 比奥根Ma公司 | 抗-bcma抗体 |
CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
EA201201435A1 (ru) | 2010-04-20 | 2013-04-30 | Генмаб А/С | ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
MX352929B (es) | 2010-11-05 | 2017-12-13 | Zymeworks Inc | DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc. |
EP2640750A1 (en) | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Agents and methods for treating diseases that correlate with bcma expression |
US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
JP6400470B2 (ja) | 2011-05-16 | 2018-10-03 | ジェネロン(シャンハイ)コーポレイション リミテッド | 多重特異性Fab融合タンパク質および使用法 |
JP6263467B2 (ja) | 2011-05-27 | 2018-01-17 | グラクソ グループ リミテッドGlaxo Group Limited | Bcma(cd269/tnfrsf17)結合タンパク質 |
JP6325979B2 (ja) | 2011-08-03 | 2018-05-16 | ザ チルドレンズ メディカル センター コーポレーション | インフルエンザ血球凝集素の受容体結合ポケットを認識する広域中和ヒト抗体 |
PT2773671T (pt) | 2011-11-04 | 2021-12-14 | Zymeworks Inc | Geração de anticorpo heterodimérico estável com mutações no domínio fc |
TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
KR20150004856A (ko) | 2012-04-20 | 2015-01-13 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | Cd3 결합 폴리펩타이드 |
CN104704004B (zh) | 2012-10-08 | 2019-12-31 | 罗切格利卡特公司 | 包含两个Fab片段的无Fc的抗体及使用方法 |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
CN104994729B (zh) | 2012-12-14 | 2019-01-11 | Omt公司 | 编码具有人独特型的啮齿动物抗体的多核苷酸以及包含所述多核苷酸的动物 |
EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
US10077315B2 (en) | 2013-02-05 | 2018-09-18 | Engmab Sàrl | Bispecific antibodies against CD3 and BCMA |
CA3115383A1 (en) | 2013-02-06 | 2014-08-14 | Celgene Corporation | Modified t lymphocytes having improved specificity |
AU2014232501C1 (en) | 2013-03-15 | 2021-04-22 | Xencor, Inc. | Heterodimeric proteins |
AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
GB201317928D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
WO2016166629A1 (en) * | 2015-04-13 | 2016-10-20 | Pfizer Inc. | Therapeutic antibodies and their uses |
CA2995754A1 (en) | 2015-08-17 | 2017-02-23 | Janssen Pharmaceutica Nv | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
JP7267914B2 (ja) * | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Bcma及びcd3に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
EP3793599A1 (en) | 2018-05-16 | 2021-03-24 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
TW202016136A (zh) | 2018-06-01 | 2020-05-01 | 瑞士商諾華公司 | 針對bcma之結合分子及其用途 |
BR112021008055A2 (pt) | 2018-10-31 | 2021-08-10 | Glaxosmithkline Intellectual Property Development Limited | métodos para determinar o prognóstico de câncer em um paciente, para prever uma resposta do paciente ao tratamento com uma proteína de ligação ao antígeno bcma, para selecionar a dose de uma proteína de ligação ao antígeno bcma e para diagnosticar câncer, composições farmacêuticas, kit e uso de uma proteína de ligação ao antígeno bcma para tratar câncer |
WO2020194243A1 (en) | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone |
US20220332821A1 (en) | 2019-06-24 | 2022-10-20 | Novartis Ag | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen |
IL292566A (en) | 2019-11-05 | 2022-06-01 | Celgene Corp | Uses of anti-bcma chimeric antigen receptors |
WO2021092060A1 (en) | 2019-11-05 | 2021-05-14 | Engmab Sarl | Methods of treatment |
IL293288A (en) | 2019-12-06 | 2022-07-01 | Regeneron Pharma | Methods for the treatment of multiple myeloma with bispecific anti-bcma and anti-cd3 antibodies |
TW202309522A (zh) | 2021-05-11 | 2023-03-01 | 美商健生生物科技公司 | 用於監測復發性及/或難治性多發性骨髓瘤之治療的方法及組成物 |
US20220411525A1 (en) | 2021-05-28 | 2022-12-29 | Janssen Pharmaceutica Nv | Bcma as a target for t cell redirecting antibodies in b cell lymphomas |
CA3237357A1 (en) * | 2021-11-03 | 2023-05-11 | Janssen Biotech, Inc. | Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies |
-
2021
- 2021-05-10 EP EP21724299.9A patent/EP4149628A1/en active Pending
- 2021-05-10 IL IL298046A patent/IL298046A/en unknown
- 2021-05-10 MX MX2022014166A patent/MX2022014166A/es unknown
- 2021-05-10 BR BR112022022800A patent/BR112022022800A2/pt unknown
- 2021-05-10 JP JP2022568563A patent/JP2023524875A/ja active Pending
- 2021-05-10 TW TW110116752A patent/TW202208429A/zh unknown
- 2021-05-10 AU AU2021272291A patent/AU2021272291A1/en active Pending
- 2021-05-10 KR KR1020227043044A patent/KR20230009450A/ko active Search and Examination
- 2021-05-10 CN CN202180034697.2A patent/CN116249548A/zh active Pending
- 2021-05-10 CA CA3182697A patent/CA3182697A1/en active Pending
- 2021-05-10 WO PCT/EP2021/062364 patent/WO2021228783A1/en active Application Filing
- 2021-05-11 US US17/317,789 patent/US11952426B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
IL298046A (en) | 2023-01-01 |
US20220041742A1 (en) | 2022-02-10 |
KR20230009450A (ko) | 2023-01-17 |
JP2023524875A (ja) | 2023-06-13 |
MX2022014166A (es) | 2022-12-02 |
AU2021272291A1 (en) | 2023-02-02 |
CN116249548A (zh) | 2023-06-09 |
CA3182697A1 (en) | 2021-11-18 |
TW202208429A (zh) | 2022-03-01 |
US11952426B2 (en) | 2024-04-09 |
WO2021228783A1 (en) | 2021-11-18 |
EP4149628A1 (en) | 2023-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022022800A2 (pt) | Métodos para tratamento de mieloma múltiplo | |
BR112018012929A2 (pt) | anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda | |
CL2020003285A1 (es) | Anticuerpos anti-psma x anti-cd28 biespecificos y usos de estos. | |
CO2021009004A2 (es) | Anticuerpos biespecíficos anti-cd28 x anti-cd22 y usos de estos | |
BR112018012801A2 (pt) | combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 para tratar o câncer | |
CL2021000131A1 (es) | Anticuerpos anti-bcma x anti-cd3 biespecíficos y usos de estos. | |
EA201791527A1 (ru) | Биспецифические антитела против плазменного калликреина и фактора xii | |
ECSP20020111A (es) | Anticuerpos de b7-h4 y métodos para usarlos | |
CR20190009A (es) | Anticuerpos anti-pd-1, un método de producción y un método para su uso. | |
BR112021024236A2 (pt) | Proteínas multiespecíficas | |
MX2019009772A (es) | Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon. | |
MA47408B1 (fr) | Traitement du cancer | |
BR112022021641A2 (pt) | Tratamento de combinação de anticorpos anti-cd40 para câncer | |
BR112022011629A2 (pt) | Anticorpos biespecíficos caninizados para tratar dermatite atópica | |
BR112023017661A2 (pt) | Inibidores de kras | |
CL2022003515A1 (es) | Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2 | |
EP4139364A4 (en) | BISPECIFIC ANTIBODIES FOR THE TREATMENT OF CD47-ASSOCIATED DISEASES | |
CO2020014343A2 (es) | Anticuerpos específicos para cd3 y sus usos | |
CL2021003215A1 (es) | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y métodos de uso de estos | |
CO2021000386A2 (es) | Anticuerpos humanizados contra psma | |
BR112021020532A2 (pt) | Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3 | |
MX2017011272A (es) | Metodo de tratamiento para la colangitis esclerosante primaria. | |
PH12020551187A1 (en) | Bispecific antigen-binding molecules and methods of use | |
BR112022001336A8 (pt) | Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo | |
BR112023004830A2 (pt) | Métodos para tratamento de mieloma múltiplo |